trifluoperazine has been researched along with Neoplasm Metastasis in 2 studies
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 6.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 2.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, S | 1 |
| Hong, J | 1 |
| Lee, JM | 1 |
| Moon, HE | 1 |
| Jeon, B | 1 |
| Choi, J | 1 |
| Yoon, NA | 1 |
| Paek, SH | 1 |
| Roh, EJ | 1 |
| Lee, CJ | 1 |
| Kang, SS | 1 |
| Budd, GT | 1 |
| Bukowski, RM | 1 |
| Lichtin, A | 1 |
| Bauer, L | 1 |
| Van Kirk, P | 1 |
| Ganapathi, R | 1 |
1 trial available for trifluoperazine and Neoplasm Metastasis
| Article | Year |
|---|---|
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer.
Topics: Adult; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Mi | 1993 |
1 other study available for trifluoperazine and Neoplasm Metastasis
| Article | Year |
|---|---|
Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R.
Topics: Animals; Antineoplastic Agents; Calcium; Calmodulin; Cell Line, Tumor; Cell Movement; Cell Survival; | 2017 |